Cited 0 times in
Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 이용준 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍범기 | - |
dc.contributor.author | 홍성진 | - |
dc.date.accessioned | 2023-07-12T02:21:59Z | - |
dc.date.available | 2023-07-12T02:21:59Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195284 | - |
dc.description.abstract | Background: Moderate-intensity statin role with ezetimibe combination therapy following percutaneous coronary intervention (PCI) has not been thoroughly investigated, particularly compared to high-intensity statin monotherapy. We aimed to investigate the effect of ezetimibe combination with moderate-intensity statin in patients with atherosclerotic cardiovascular disease following PCI. Methods: This was a post-hoc analysis of a subset of patients who underwent PCI in the RACING trial. At 26 centres in South Korea, patients with atherosclerotic cardiovascular disease (ASCVD) were randomly assigned to receive either moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg) or high-intensity statin monotherapy (rosuvastatin 20 mg). The prespecified endpoints of the RACING trial were used. The primary endpoint was the 3-year composite of cardiovascular death, major cardiovascular events, and nonfatal stroke. Event rates between the two groups were compared using log-rank tests, and hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox regression analysis. Consistent with the RACING trial, the primary and secondary efficacy endpoints were evaluated using an intention-to-treatment approach, and the safety endpoints were assessed in the safety population. The RACING trial was registered at ClinicalTrials.gov (NCT03044665). Findings: Between Feb 14, 2017, and Dec 18, 2018, 3780 participants were enrolled in the RACING trial. Prior history of PCI was found in 2497 patients (67%, median 64 years, 79% male), and was associated with higher rates of the primary endpoint (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.06–1.69; p = 0.014). Among patients with prior PCI, moderate-intensity statin therapy with ezetimibe combination versus high-intensity statin therapy did not increase the risk of the primary endpoint (HR, 0.95; 95% CI, 0.74–1.24; p = 0.781). The proportion of patients with low-density lipoprotein cholesterol (LDL-C) <70 mg/dL at 1, 2, and 3 years was 74%, 76%, and 73%, respectively, in the combination therapy group, and was significantly higher than that in the high-intensity statin monotherapy group (57%, 62%, and 59%, respectively, all p < 0.001). Discontinuation of lipid-lowering drugs occurred less frequently in the combination group (4.2% vs. 7.6%, p = 0.001). Interpretation: The effects of ezetimibe combination therapy observed in the RACING trial were consistently preserved among patients with ASCVD following PCI. Ezetimibe combination could be considered as a suitable therapeutic strategy to achieve strict control of LDL-C and reduce drug intolerance in patients who underwent PCI. Funding: Hanmi Pharmaceutical, Seoul, South Korea © 2026 The Author(s) | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | The Lancet | - |
dc.relation.isPartOf | ECLINICALMEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jong-Il Park | - |
dc.contributor.googleauthor | Seung-Jun Lee | - |
dc.contributor.googleauthor | Bum-Kee Hong | - |
dc.contributor.googleauthor | Yun-Hyeong Cho | - |
dc.contributor.googleauthor | Won-Yong Shin | - |
dc.contributor.googleauthor | Sang-Wook Lim | - |
dc.contributor.googleauthor | Woong-Chol Kang | - |
dc.contributor.googleauthor | Yongwhi Park | - |
dc.contributor.googleauthor | Sung-Yoon Lee | - |
dc.contributor.googleauthor | Yong-Joon Lee | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | RACING investigators | - |
dc.identifier.doi | 10.1016/j.eclinm.2023.101933 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A02927 | - |
dc.contributor.localId | A02984 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04394 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J04145 | - |
dc.identifier.eissn | 2589-5370 | - |
dc.identifier.pmid | 37090440 | - |
dc.subject.keyword | Dyslipidaemias | - |
dc.subject.keyword | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keyword | Percutaneous coronary intervention\ | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 이승준 | - |
dc.contributor.affiliatedAuthor | 이용준 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍범기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 58 | - |
dc.citation.startPage | 101933 | - |
dc.identifier.bibliographicCitation | ECLINICALMEDICINE, Vol.58 : 101933, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.